Levosertone

Levonorgestrel, the active ingredient in Levosertone, is a progestogen (progestin) presented as an intrauterine system for intrauterine use. It prevents pregnancy and can be used to manage heavy menstrual bleeding. GNH USA supplies Levosertone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levosertone, a levonorgestrel‑based intrauterine system, is used in hormonal contraceptive pathways and menstrual management.

Contraception: provides long‑term, reversible birth control for women of reproductive age. Heavy menstrual bleeding: reduces menstrual blood loss and improves anemia associated with excessive bleeding.

Levosertone may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Irregular bleeding or spotting, especially during the first months. - Amenorrhea (absence of periods) after prolonged use. - Pelvic or uterine cramping after insertion. - Breast tenderness or mild hormonal changes.

Serious or Rare Side Effects: - Pelvic inflammatory disease or uterine infection. - Uterine perforation during insertion. - Expulsion of the device requiring medical attention.

Before prescribing Levosertone, clinicians should consider several safety measures.

Screen for pregnancy: confirm the patient is not pregnant prior to insertion. Assess uterine size and shape: verify suitability for an intrauterine system. Review medical history: avoid use in active pelvic infection, uterine anomalies, or hormone‑sensitive cancers. Monitor bleeding patterns: counsel patients on expected changes and when to seek care. Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levosertone can interact with other medicines that affect hormone metabolism.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce levonorgestrel efficacy. - Rifampin: can lower hormone levels and increase risk of contraceptive failure. - Protease inhibitor antiretrovirals: may alter levonorgestrel metabolism.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., ketoconazole): may increase levonorgestrel concentrations. - Certain antibiotics (e.g., tetracycline): have minimal effect but should be monitored for any changes in bleeding.